Clinical Trial Update: A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 1]

View source ↗

Summary

Phase 1 study of belantamab mafodotin in relapsed/refractory multiple myeloma has completed, with results posted detailing safety, tolerability, pharmacokinetic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2024-04-19